Starling Oncology
STLN
6.28
-0.16
-2.41%
Starling Oncology
US · STLN
#3565 by market cap
6.28
-0.16
-2.41%
Live - 5344 symbols - heartbeat 406s ago
· 2026-10-08 10:10
Pre-market
6.40
-0.47%
After-hours
6.43
0.00%
- Market cap
- 639.52M
- P/E (TTM)i
- -21.64
- P/Bi
- -25.72
- EPSi
- -0.54
- Div yieldi
- 0.00%
- 52W posi
- 82%
Reader sentiment
Are you bullish or bearish on STLN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Fair
- Altman Z-Score is 2.45, in the 1.8-3.0 "grey zone".
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 7 years
Latest year +27.79% YoY
Margins
- Gross margin
- 15.20%
- Operating margin
- -7.18%
- Net margin
- -10.01%
Key ratios & quality
- Enterprise valuei
- 690.51M
- Altman Z-Scorei
- 2.45
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 155.41M | 187.52M | 203.00M | 252.48M | 324.24M | 393.41M | 502.73M |
| Gross profit | 29.94M | 36.88M | 40.85M | 52.09M | 59.57M | 54.00M | 76.44M |
| Selling & admin expenses | 29.64M | 41.90M | 83.37M | 119.69M | 113.85M | 107.83M | 105.57M |
| Research & development | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | -2.64M | -8.20M | -45.86M | -72.01M | -60.15M | -60.12M | -36.08M |
| Pretax profit | -2.64M | -14.82M | -11.60M | -91.00K | -83.10M | -64.66M | -60.74M |
| Tax | 1.38M | -493.00K | -671.00K | -243.00K | -36.00K | 0 | -131.00K |
| Net profit | -4.02M | -14.32M | -10.93M | 152.00K | -83.07M | -64.66M | -60.61M |
| Basic EPS | 0 | 0 | 0 | 0 | -1 | -1 | -1 |
| Diluted EPS | -0.06 | -0.22 | -0.16 | -0.21 | -0.92 | -0.71 | -0.54 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 104.41M | 119.80M | 136.56M | 141.96M | 147.44M | 161.28M |
| Gross profit | 17.25M | 17.50M | 18.92M | 22.77M | 23.32M | 27.17M |
| Selling & admin expenses | 25.38M | 26.91M | 25.25M | 28.04M | 28.21M | 29.94M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | -9.91M | -11.21M | -8.05M | -6.91M | -6.51M | -4.62M |
| Pretax profit | -19.59M | -17.14M | -16.50M | -7.51M | -2.49M | -9.79M |
| Tax | 0 | -131.00K | 0 | 0 | 0 | 0 |
| Net profit | -19.59M | -17.01M | -16.50M | -7.51M | -2.49M | -9.79M |
| Basic EPS | 0 | 0 | 0 | 0 | 0 | 0 |
| Diluted EPS | -0.21 | -0.15 | -0.14 | -0.06 | -0.02 | -0.08 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Total current assets | 21.79M | 29.72M | 154.06M | 130.42M | 143.49M | 112.42M | 112.75M |
| Cash & ST investments | 2.45M | 6.00M | 114.30M | 73.81M | 82.86M | 49.67M | 33.57M |
| Inventory | 3.89M | 4.35M | 6.44M | 9.26M | 13.68M | 10.04M | 16.88M |
| Total assets | 59.52M | 65.69M | 203.44M | 261.67M | 209.24M | 172.72M | 164.66M |
| Total current liabilities | 13.59M | 28.61M | 29.80M | 29.72M | 34.79M | 52.22M | 70.96M |
| Short-term debt | -- | 5.37M | 183.00K | 5.50M | 6.36M | 6.80M | 7.16M |
| Long-term debt | -- | 6.56M | -- | 80.62M | 86.83M | 93.13M | 77.40M |
| Total liabilities | 17,298,392.00 | 37,588,000.00 | 99,280,000.00 | 138,490,000.00 | 152,215,000.00 | 169,128,000.00 | 180,376,000.00 |
| Total equity | 42.22M | 28.10M | 104.16M | 123.18M | 57.03M | 3.59M | -15.72M |
| Retained earnings | -6.02M | -52.31M | -63.23M | -63.08M | -146.15M | -210.81M | -271.42M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 106.82M | 104.79M | 110.09M | 112.75M | 116.86M | 128.99M |
| Cash & ST investments | 39.74M | 30.29M | 27.66M | 33.57M | 30.28M | 41.09M |
| Inventory | 12.31M | 15.79M | 18.88M | 16.88M | 24.29M | 20.01M |
| Total assets | 164.00M | 159.80M | 163.62M | 164.66M | 168.23M | 178.23M |
| Total current liabilities | 59.54M | 64.78M | 65.58M | 70.96M | 79.35M | 94.94M |
| Short-term debt | 6.82M | 6.95M | 7.16M | 7.16M | 7.40M | 7.23M |
| Long-term debt | 73.89M | 75.02M | 76.20M | 77.40M | 78.61M | 79.87M |
| Total liabilities | 158,933,000.00 | 168,783,000.00 | 175,893,000.00 | 180,376,000.00 | 184,515,000.00 | 203,147,000.00 |
| Total equity | 5.07M | -8.99M | -12.27M | -15.72M | -16.29M | -24.91M |
| Retained earnings | -230.40M | -247.41M | -263.91M | -271.42M | -273.91M | -283.70M |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | 3.62M | 508.00K | -32.68M | -61.76M | -36.32M | -26.54M | -24.59M |
| Depreciation & amortization | 2.94M | 3.18M | 3.34M | 4.41M | 5.87M | 6.29M | 6.94M |
| Free cash flow | 2.41M | -686.00K | -35.73M | -67.29M | -40.88M | -30.33M | -27.79M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | 0 | -9.00M | -1.02M | 0 | 29.20M |
| Ending cash balance | 2.45M | 6.00M | 115.17M | 14.01M | 33.49M | 49.67M | 33.57M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -4.99M | -10.20M | -12.63M | 3.23M | -2.22M | 11.94M |
| Depreciation & amortization | 1.78M | 1.81M | 1.72M | 1.63M | 1.62M | 1.84M |
| Free cash flow | -5.32M | -11.41M | -13.23M | 2.17M | -3.26M | 11.03M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 15.36M | 0 | 9.95M | 3.89M | 0 | 0 |
| Ending cash balance | 39.74M | 30.29M | 27.66M | 33.57M | 30.28M | 41.09M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| ROE %i | -- | -- | -41.91 | 0.06 | -75.34 | -174.89 | -- |
| ROA %i | -6.76 | -22.88 | -8.12 | 0.03 | -28.83 | -27.75 | -29.82 |
| ROIC %i | -- | -- | -36.83 | 1.50 | -29.95 | -30.00 | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -79.08 | -- |
| EBIT margin %i | -1.70 | -7.72 | -5.56 | 1.58 | -23.54 | -14.53 | -9.84 |
| FCF / sales %i | 1.55 | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.60 | 1.04 | 5.17 | 4.39 | 4.12 | 2.15 | 1.59 |
| Quick ratioi | 1.26 | 0.81 | 4.55 | 3.84 | 3.62 | 1.88 | 1.31 |
| Debt / assetsi | -- | 18.16 | 0.09 | 41.34 | 57.20 | 71.30 | 62.97 |
| LT debt / equityi | -- | 23.35 | -- | 83.36 | 198.71 | 3,241.96 | -- |
| Interest coveragei | -780.67 | -41.68 | -35.24 | 0.98 | -11.26 | -7.63 | -4.39 |
| Revenue CAGR (3Y) %i | -- | -- | 21.51 | 17.56 | 20.03 | 24.68 | 25.81 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -227.79 | -535.32 | -3,410.47 | -- | -- | -- |
| ROA %i | -28.66 | -31.89 | -31.92 | -29.82 | -21.87 | -18.08 |
| ROIC %i | -31.08 | -35.45 | -38.48 | -- | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -13.22 | -13.00 | -12.12 | -9.84 | -6.60 | -4.88 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 1.79 | 1.62 | 1.68 | 1.59 | 1.47 | 1.36 |
| Quick ratioi | 1.50 | 1.33 | 1.34 | 1.31 | 1.13 | 1.14 |
| Debt / assetsi | 62.38 | 64.55 | 63.29 | 62.97 | 62.33 | 58.62 |
| LT debt / equityi | 1,883.80 | -- | -- | -- | -- | -- |
| Interest coveragei | -4.81 | -5.09 | -5.31 | -4.39 | -4.71 | -3.76 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Specialty Pharmacy is the largest reported line at 61.14% of revenue, across 3 reported segments.
- Patient Services follows at 36.47%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Specialty Pharmacy61.14%
Patient Services36.47%
Clinical trials & other2.39%
Quote time 2026-10-08 10:10:35 · For reference only, not investment advice and not tailored to your situation.